United States - English - NLM (National Library of Medicine)

nucare pharmaceuticals,inc. - ceftriaxone sodium (unii: 023z5br09k) (ceftriaxone - unii:75j73v1629) - ceftriaxone 1 g - before instituting treatment with ceftriaxone, appropriate specimens should be obtained for isolation of the causative organism and for determination of its susceptibility to the drug. therapy may be instituted prior to obtaining results of susceptibility testing. to reduce the development of drug-resistant bacteria and maintain the effectiveness of ceftriaxone for injection, usp and other antibacterial drugs, ceftriaxone for injection, usp should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. when culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. in the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. ceftriaxone for injection, usp is indicated for the treatment of the following infections when caused by susceptible organisms: caused by streptococcus pneumoniae , staphylococcus aureus,

United States - English - NLM (National Library of Medicine)

nucare pharmaceuticals, inc. - ceftriaxone sodium (unii: 023z5br09k) (ceftriaxone - unii:75j73v1629) - ceftriaxone 250 mg - before instituting treatment with ceftriaxone, appropriate specimens should be obtained for isolation of the causative organism and for determination of its susceptibility to the drug. therapy may be instituted prior to obtaining results of susceptibility testing. to reduce the development of drug-resistant bacteria and maintain the effectiveness of ceftriaxone for injection, usp and other antibacterial drugs, ceftriaxone for injection, usp should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. when culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. in the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. ceftriaxone for injection, usp is indicated for the treatment of the following infections when caused by susceptible organisms: caused by streptococcus pneumoniae , staphylococcus aureus,

United States - English - NLM (National Library of Medicine)

sandoz gmbh - ceftriaxone sodium (unii: 023z5br09k) (ceftriaxone - unii:75j73v1629) - ceftriaxone 250 mg - before instituting treatment with ceftriaxone, appropriate specimens should be obtained for isolation of the causative organism and for determination of its susceptibility to the drug. therapy may be instituted prior to obtaining results of susceptibility testing. to reduce the development of drug-resistant bacteria and maintain the effectiveness of ceftriaxone for injection, usp and other antibacterial drugs, ceftriaxone for injection, usp should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. when culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. in the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. ceftriaxone for injection, usp is indicated for the treatment of the following infections when caused by susceptible organisms: caused by streptococcus pneumoniae , staphylococcus aureus, ha

United States - English - NLM (National Library of Medicine)

cardinal health - ceftriaxone sodium (unii: 023z5br09k) (ceftriaxone - unii:75j73v1629) - ceftriaxone 1 g - before instituting treatment with ceftriaxone, appropriate specimens should be obtained for isolation of the causative organism and for determination of its susceptibility to the drug. therapy may be instituted prior to obtaining results of susceptibility testing. to reduce the development of drug-resistant bacteria and maintain the effectiveness of ceftriaxone for injection, usp and other antibacterial drugs, ceftriaxone for injection, usp should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. when culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. in the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. ceftriaxone for injection, usp is indicated for the treatment of the following infections when caused by susceptible organisms: caused by streptococcus pneumoniae , staphylococcus aureus, ha

Israel - English - Ministry of Health

vitamed pharmaceutical industries ltd - ceftriaxone as disodium hemiheptahydrate - powder for solution for injection - ceftriaxone as disodium hemiheptahydrate 1.0 g/vial - ceftriaxone - ceftriaxone vit is indicated for the treatment of the following infections in adults andchildren including term neonates (from birth):-bacterial meningitis- community acquired pneumonia-hospital acquired pneumonia-acute otitis media-intra-abdominal infections-complicated urinary tract infections (including pyelonephritis)-infections of bones and joints-complicated skin and soft tissue infections-gonorrhoea-syphilis-bacterial endocarditisceftriaxone vit may be used:- for treatment of acute exacerbations of chronic obstructive pulmonary diseasein adults- for treatment of disseminated lyme borreliosis (early (stage ii) and late (stageiii) in adults and children including neonates from 15 days of age.- for pre-operative prophylaxis of surgical site infections-in the management of neutropenic patients with fever that is suspected to be dueto a ceftriaxone – susceptible bacterial infection- in the treatment of patients with bacteraemia that occurs in association with, oris suspected to be associated with, any of the infections listed aboveceftriaxone vit should be co-administered with other antibacterial agents whenever thepossible range of causative bacteria would not fall within its spectrum.

Israel - English - Ministry of Health

k.s.kim international (sk- pharma) ltd., israel - ceftriaxone as sodium - powder for solution for injection - ceftriaxone as sodium 1000 mg/vial - ceftriaxone - ceftriaxone s.k. is indicated for the treatment of the following infections in adults and children including term neonates (from birth): - bacterial meningitis - community acquired pneumonia - hospital acquired pneumonia - acute otitis media - intra-abdominal infections - complicated urinary tract infections (including pyelonephritis) - infections of bones and joints - complicated skin and soft tissue infections - gonorrhoea - syphilis - bacterial endocarditisceftriaxone s.k. may be used: - for treatment of acute exacerbations of chronic obstructive pulmonary disease in adults - for treatment of disseminated lyme borreliosis (early (stage ii) and late (stage iii) in adults and children including neonates from 15 days of age. - for pre-operative prophylaxis of surgical site infections - in the management of neutropenic patients with fever that is suspected to be due to a ceftriaxone – susceptible bacterial infection - in the treatment of patients with bacteraemia that occurs in association with, or is suspected to be associated with, any of the infections listed above

New Zealand - English - Medsafe (Medicines Safety Authority)

viatris limited - ceftriaxone sodium 2.158 g (present as 2.386g ceftriaxone na*3.5h2o. eq 2.158g of ceftriaxone na anhyd or 2g ceftriaxone anhyd) - powder for infusion - 2 g - active: ceftriaxone sodium 2.158 g (present as 2.386g ceftriaxone na*3.5h2o. eq 2.158g of ceftriaxone na anhyd or 2g ceftriaxone anhyd) - infections caused by pathogens sensitive to ceftriaxone e.g.: - sepsis; - meningitis; - abdominal infections (peritonitis, infections of the biliary and gastrointestinal tracts); - infections of the bones, joints, soft tissue, skin and of wounds; - infections in patients with impaired defence mechanisms; - renal and urinary tract infections; - respiratory tract infections, particularly pneumonia, and ear, nose and throat infections; - genital infections, including gonorrhoea. - perioperative prophylaxis of infections.

New Zealand - English - Medsafe (Medicines Safety Authority)

douglas pharmaceuticals limited - ceftriaxone sodium 1079.3mg (present as 1.193g ceftriaxone na*3.5h2o. eq 1.0793g of ceftriaxone na anhyd or 1g ceftriaxone anhyd) - powder for injection - 1000 mg - active: ceftriaxone sodium 1079.3mg (present as 1.193g ceftriaxone na*3.5h2o. eq 1.0793g of ceftriaxone na anhyd or 1g ceftriaxone anhyd)

New Zealand - English - Medsafe (Medicines Safety Authority)

aft pharmaceuticals ltd - ceftriaxone sodium 1079.3mg (present as 1.193g ceftriaxone na*3.5h2o. eq 1.0793g of ceftriaxone na anhyd or 1g ceftriaxone anhyd) - powder for injection - 1 g - active: ceftriaxone sodium 1079.3mg (present as 1.193g ceftriaxone na*3.5h2o. eq 1.0793g of ceftriaxone na anhyd or 1g ceftriaxone anhyd)

New Zealand - English - Medsafe (Medicines Safety Authority)

douglas pharmaceuticals limited - ceftriaxone sodium 2158.6mg (present as 2.386g ceftriaxone na*3.5h2o. eq 2.158g of ceftriaxone na anhyd or 2g ceftriaxone anhyd) - powder for injection - 2000 mg - active: ceftriaxone sodium 2158.6mg (present as 2.386g ceftriaxone na*3.5h2o. eq 2.158g of ceftriaxone na anhyd or 2g ceftriaxone anhyd)